Androgens in women before and after the menopause and post bilateral oophorectomy: Clinical effects and indications for testosterone therapy

Women's Health

Volumn 8, Issue 4, 2012, Pages 437-446

  Davey, Dennis A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

androgens; HRT; hypoactive sexual desire disorder; libido; menopause; oophorectomy; testosterone; transdermal therapy; women

Indexed keywords

ANDROSTENEDIONE; CONJUGATED ESTROGEN; CORTICOSTEROID; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; METHYLTESTOSTERONE; PLACEBO; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

AGE; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; BODY COMPOSITION; BONE DENSITY; BREAST CANCER; CARDIOVASCULAR DISEASE; COGNITION; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM; ESTROGEN THERAPY; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; HYSTERECTOMY; LEAN BODY WEIGHT; LIBIDO DISORDER; LIPID BLOOD LEVEL; MENOPAUSE; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANDROGENS; BODY MASS INDEX; BONE DENSITY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; OVARIECTOMY; PERIMENOPAUSE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 84863585212     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.12.27     Document Type: Review

References (66)

1. Burger HG. Androgen production in women. Fertil. Steril. 77(Suppl. 4), S3-S5 (2002). (Pubitemid 34465837)
2. Dunn J, Nisula B, Rodbard D. Transport of steroid hormones: Binding 21 endogenous steroids to both testosterone-binding and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab. 53, 58-68 (1981). (Pubitemid 13245381)
3. Miller KK, Rosner W, Lee H et al. Measurement of free testosterone in normal women and women with androgen deficiency: Comparison of methods. J. Clin. Endocrinol. Metab. 9, 525-533 (2004). (Pubitemid 38269853)
4. Tremblay RR, Dube JY. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception 10, 599-605 (1974).
5. Haring R, Hanneman A, John U et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J. Clin. Endocrinol. Metab. 97, 408-415 (2012).
6. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84, 3666-3672 (1999). (Pubitemid 30645223)
7. Rothman MS, Carlson NE, Xu M et al. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography tandem mass spectrometry. Steroids 76, 177-182 (2011).
8. Fanelli F. Belluomo I, Lallo VD et al. Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: Comparison with current immunoassays and reference intervals in healthy adults. Steroids 76, 244-253 (2011).
9. Demers LM. Androgen deficiency in women; role of accurate testosterone measurements. Maturitas 67, 39-45 (2010).
10. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: Changes with age, menopause and oophorectomy. J. Clin. Endocrinol. Metab. 90, 3847-3853 (2005). (Pubitemid 41058142)
11. Burger HG, Papalia MA. A clinical update on female androgen deficiency testosterone testing and treatment in women presenting with low sexual desire. Sex. Health 3, 73-78 (2006). (Pubitemid 43829302)
12. Cappola AR, Ratcliffe SJ, Bhasin S et al. Determinants of serum total and free testosterone levels in women over age of 65 years. J. Clin. Endocrinol. Metab. 92, 5009-5016 (2007).
13. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of testosterone, dehydroepiandrosterone sulfate and sex-hormone binding globulin through the menopause transition. J. Endocrinol. Metab. 85, 2832-2838 (2000). (Pubitemid 32269161)
14. Fogle RH, Stanczk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. J. Clin. Endocrinol. Metab. 92, 3040-3043 (2007). (Pubitemid 47236368)
15. Chakravarti S, Collins WP, Newton JR, Oram DH, Studd JW. Endocrine changes after oophorectomy in premenopausal women. Br. J. Obstet. Gynaecol. 84, 769-775 (1977). (Pubitemid 8198589)
16. Laughlin GA, Barrett-Connor E, Kritz- Silverstein D, von Muhlen D. Hysterectomy, oophorectomy and endogenous sex hormone levels in older women: The Rancho Bernado Study. J. Clin. Endocrinol. Metab. 85, 645-651 (2000). (Pubitemid 32273648)
17. Ethun KF, Wood CE, Parker CR, Kaplan JR, Chen H, Appt SE. Effect of ovarian aging on androgen biosynthesis in a cynomolgus macaque model. Climacteric 15, 82-92 (2012).
18. Endogenous hormones and breast cancer collaborative group. Circulating sex hormones and breast cancer risk factors in postmenopausal women: Reanalysis of 13 studies. Br. J. Cancer 105, 709-722 (2011).
19. Santoro N, Torrens J, Crawford S et al. Correlates of circulating androgens in midlife women: The Study of Women's Health Across the Nation. J. Clin. Endocrinol. Metab. 90, 4836-4845 (2005). (Pubitemid 41159380)
20. Murphy A, Cropp CS, Smith BS, Burkman RT, Zacur HA. Effect of low-dose oral contraceptive on gonadotrophins, androgens and sex hormone-binding globulin in non-hirsute women. Fertil. Steril. 53, 35-39 (1990). (Pubitemid 20041312)
21. Miller KK, Sesmilo G, Schiller A, Schoenfeld D, Burton S, Klibanski A. Androgen deficiency in women with hypopituitarism. J. Clin. Endocrinol. Metab. 86, 561-567 (2001). (Pubitemid 32207459)
22. Simon JA. Estrogen replacement therapy: Effects in the endogenous androgen milieu. Fertil. Steril. 7, S77-S82 (2002). (Pubitemid 34465849)
23. Kotsopoulos J, Narod S. Androgens and breast cancer. Steroids 77, 1-9 (2012).
24. Hofling M, Hirschberg AL, Skoog L, Tani E, Hagerstrom T, von Schoultz B. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 14, 183-190 (2007). (Pubitemid 46673468)
25. Davis SR, Wolfe R, Farrugi AH, Ferdinand A, Bell RJ. The incidence of invasive breast cancer among women prescribed testosterone for low libido. J. Sex. Med. 6, 1850-1856 (2009).
26. Park S, Koo JS, Kim HS et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann. Oncol. 22, 1755-1762 (2011).
27. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 11, 531-535 (2004). (Pubitemid 40362151)
28. Zang H, Sahlin L, Masironi B, Eriksson E, Linden Hirschberg A. Effects of testosterone on endometrial proliferation in postmenopausal women. J. Clin. Endocrinol. Metab. 92, 2169-1675 (2007).
29. Wood CE, Lees CJ, Cline JM. Mammary gland and endometrial effects of testosterone in combination with oral estradiol and progesterone. Menopause 16, 466-476 (2002).
30. Rairy CM, Ratcliffe SJ, Weinstein R et al. serum free testosterone in older women is associated with greater bone mineral density, lean body mass and total fat mass: The cardiovascular health study. J. Clin. Endocrinol. Metab. 96, 989-996 (2011).
31. Davis S, Walker K, Strauss B. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause 7, 395-401 (2000).
32. Miller KK, Biller BM, Beauregard C et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: A randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 91, 1683-1690 (2006).
33. Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343, 682-688 (2000).
34. Ouyang P, Vaidya D, Dobs A et al. Sex hormone levels and subclinical atherosclerosis in postmenopausal women: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 204, 255-261 (2009).
35. Braunstein GD, Johnson BD, Stanczyk FZ et al. Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease. J. Clin. Endocrinol. Metab. 93, 4268-4275 (2008). (Pubitemid 352789521)
36. Calderon-Margalit R, Schwartz SM, Wellons MF et al. Prospective association of serum androgens and sex hormone-binding globulin in subclinical cardiovascular disease in young adult women: The "Coronary Artery Risk Development in Young Adults" women's study. J. Clin. Endocrinol. Metab. 95, 4424-4431 (2010).
37. Barrett-Connor E, Goodman-Gruen D. Prospective study of exogenous sex hormones and fatal cardiovascular disease in postmenopausal women. Br. Med. J. 311, 1193-1196 (1995).
38. Siemenda C, Longcope C, Peacock M, Hui S, Johnston CC. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-And postmenopausal women. J. Clin. Invest. 97, 14-21 (1996).
39. Greendale GA, Edelstein S, Barrett-Connor. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernando Study. J. Bone Miner. Res. 12, 1833-1843 (1997). (Pubitemid 27500195)
40. van Geel TA, Geusens PP, Winkens B, Sels JP, Dinant GJ. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle mass, muscle strength and bone mineral density in postmenopausal women: A cross-sectional study. Eur. J. Endocrinol. 160, 681-687 (2009).
41. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 21, 227-236 (1995).
42. Barrett-Connor E, Young R, Notelowitz M et al. A two-year, double-blind comparison of estrogen-Androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J. Reprod. Med. 44, 1012-1020 (1999). (Pubitemid 30030175)
43. Henderson VW. Gonadal hormones and cognitive aging. Women's Health (Lond.) 7, 81-93 (2011).
44. Ryan J, Stanczyk FZ, Dennerstein L et al. Hormone levels and cognitive function in postmenopausal midlife women. Neurobiol. Aging 33, 617.e11-e22 (2012).
45. Thilers PP, Macdonald S, Helitz A. The association between endogenous free testosterone and cognitive performance: A population-based study in 35 to 90 year old men and women. Psychoneuroendocrinology 31, 565-576 (2006).
46. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 13, 345-357 (1988).
47. Miller KK. Androgen deficiency in women. J. Clin. Endocrinol. Metab. 86, 2395-2401 (2001).
48. Basson R, Brotto LA, Petkau J, Labrie F. Role of androgens in women's sexual dysfunction. Menopause 5, 932-971 (2010).
49. Brotto LA, Bitzer J, Laan E, Leiblum S, Luria M. Women's sexual desire and arousal disorders. J. Sex. Med. 7, 586-614 (2010).
50. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). Text Revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, USA (2000).
51. Dennerstein L, Kochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: A survey of Western European women. J. Sex. Med. 3, 212-222 (2006).
52. Bachmann G, Bancroft J, Braunstein G et al. Female androgen deficiency: The Princeton consensus statement on definition, classification and assessment. Fertil. Steril. 77, 660-665 (2002). (Pubitemid 34275339)
53. North American Menopause Society. The role of testosterone therapy in postmenopausal women: Position statement of the North American Menopause Society. Menopause 12, 496-511 (2005).
54. Sturdee DW, Pines A. On behalf of the International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 14, 302-320 (2011).
55. Weisman ME, Basson R, Davis SR et al. Androgen therapy in women: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 91, 3697-3710 (2006). (Pubitemid 44536831)
56. Greenblatt RB, Barfield WE, Garner JF, Calk GL, Harrod JP. Evaluation of an estrogen, androgen, estrogen-Androgen combination, and a placebo in the treatment of the menopause. J. Clin. Endocrinol. Metab. 10, 1547-1558 (1950).
57. Somnoonporn W, Davis S, Sief M, Bell R. Testosterone for peri- and post- menopausal women. Cochrane Database Syst. Rev. 4, CD004509 (2005).
58. Floter A, Nathorst-Boos J, Carlstrom K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: Effects on sexuality and well-being. Climacteric 5, 357-365 (2002). (Pubitemid 36149723)
59. Braunstein GD, Sundwall DA, Katz M et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire in surgically menopausal women: A randomized, placebo-controlled trial. Arch. Intern. Med. 165, 1582-1589 (2005). (Pubitemid 41124151)
60. Shifren JL, Davis SR, Moreau M et al. Testosterone patch for the treatment of hypoactive desire disorder in naturally menopausal women: The results from the INTIMATE NM1 Study. Menopause 13, 770-779 (2006).
61. Simon JA, Brunstein G, Nachtigll L et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J. Clin. Endocrinol. Metab. 90, 5226-5263 (2005).
62. Buster JE, Kingsberg SA, Aquirre O et al. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet. Gynecol. 105, 944-952 (2005). (Pubitemid 40571010)
63. Davis SR, van den Mooren, van Lunsen RH et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized placebo-controlled trial. Menopause 13, 387-396 (2006).
64. Davis S, Moreau M, Kroll R et al. Testosterone for low libido in postmenopausal women not taking estrogens. N. Engl. J. Med. 359, 2005-2017 (2008).
65. Panay N, Al-Azzawi F, Bouchard C et al. Testosterone treatment of HSSD in naturally menopausal women. Climacteric 13, 121-131 (2010).
66. Nachtigall L, Casson P, Lucas L, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch for therapy for up to 4 years in surgically menopausal women receiving oral or transdermal estrogen. Gynecol. Endocrinol. 27, 39-48 (2011).